Liberation Bioindustries
PrivateLast Round
Series A
Dec 19, 2025
Est. Valuation
$59.9M
Total Funding Raised
$146.89M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
Liberation Bioindustries operates in Healthcare & Life Sciences and is based in New York City, New York. Its latest recorded funding round was a Series A round in December 2025.
Liberation Bioindustries is a biotechnology and manufacturing company that designs, builds, and operates a global network of purpose-built, commercial-scale precision fermentation facilities.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clean Manufacturing
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Liberation Bioindustries Comparables
Compare Liberation Bioindustries with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Cauldron | 86% | |
| ScaleUp Bio | 81% | |
| Planetary | 81% |
For institutional investors. Book with your work email.
Liberation Bioindustries Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Dec 19, 2025 | ||||
| Series A Extension | Dec 19, 2025 | ||||
| Convertible Debt | Jan 29, 2025 | ||||
| Grant | Oct 15, 2024 | ||||
| Convertible Debt | Apr 8, 2024 | ||||
Seed | Jan 3, 2023 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Liberation Bioindustries Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Agronomics Limited | Convertible Debt, Series A Extension, Series A, Seed |
| Echo | Seed |
| CPT Capital | Seed |
| Thia Ventures | Seed |
| NEOM Investment Fund | Convertible Debt |
| Echo Investment Capital | Seed |
| Meach Cove Capital | Convertible Debt |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Nov 1, 2026
Open roles increased to 13, 65% of headcount.
- Apr 22, 2026
Building a precision fermentation facility in Richmond, Indiana.
For institutional investors. Book with your work email.
Liberation Bioindustries Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Liberation Bioindustries's valuation, stock price, and market status.
Is Liberation Bioindustries a public or private company?
Liberation Bioindustries is a private company.
What is the current stock price of Liberation Bioindustries?
Liberation Bioindustries is a private company, so its shares have no public market price. Caplight tracks Liberation Bioindustries's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Liberation Bioindustries worth (valuation)?
Liberation Bioindustries's valuation is estimated at $59.9M based on funding round data.
Can I buy Liberation Bioindustries stock?
Liberation Bioindustries shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Liberation Bioindustries's last funding round?
Liberation Bioindustries's most recent funding round was Series A on December 19, 2025.
Who are the main investors in Liberation Bioindustries?
Key investors in Liberation Bioindustries include Agronomics Limited, Siddhi Capital.
Will Liberation Bioindustries IPO soon?
No public IPO plans have been announced for Liberation Bioindustries.
How can I track Liberation Bioindustries secondary market activity?
Caplight tracks bids, offers, and trades in Liberation Bioindustries's shares on secondary markets.